Literature DB >> 9226199

Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer.

F Grünwald1, C Menzel, H Bender, H Palmedo, P Willkomm, J Ruhlmann, T Franckson, H J Biersack.   

Abstract

18Fluorine-fluorodeoxyglucose (FDG) positron-emission tomography (PET) has emerged as a useful method in various fields of oncology. The aim of the present study was to evaluate the clinical significance of this technique in differentiated thyroid carcinoma and to compare the results with other imaging modalities, particularly with whole-body 131iodine scintigraphy (WBS) and hexakis (2-methoxyisobutylisonitrile) (99m)technetium (I) scintigraphy (MIBI). Whole-body PET imaging using FDG was performed in 54 patients. There were 39 patients with papillary tumors and 15 patients with follicular tumors (including 3 Hürthle-cell carcinomas). Primary tumor stage (pT) was pT1 in 5 cases, pT2 in 19 cases, pT3 in 2 cases, pT4 in 24 cases, and unknown in 4 cases, respectively. Finally, for each case an overall clinical evaluation was done including histology, cytology, thyroglobulin level, sonography, computed tomography, magnetic resonance imaging, and subsequent clinical course, to allow a comparison with functional imaging results. Compared with WBS, FDG-PET gave different results in the majority of cases with recurrence/metastases (11 FDG-true-positive/WBS-negative tumor sites and 8 WBS-true-positive/FDG-negative tumor sites). In 7 patients with recurrence/metastases, FDG-PET and WBS gave corresponding results (10 sites). In 28 patients, FDG-PET and WBS were normal (including 2 false-negative cases). MIBI was performed in 44 cases. FDG-PET was better correlated to MIBI (congruent positive results in 13 tumor sites) than to WBS. Compared with MIBI, FDG-PET was superior in 5 cases (including 3 patients with distant metastases). Two FDG-negative/MIBI-positive tumors were observed. Different tracer uptake mechanisms have to be considered regarding "nonspecific" tumor imaging with FDG-PET or MIBI. Nevertheless, since spatial resolution with respect to tomographic imaging is inferior with single photon emission computer tomography (SPECT) using MIBI, the observed higher sensitivity of PET might be due to the higher spatial resolution of this method. As far as grading could be obtained, FDG-PET seemed to be more sensitive than WBS in high-grade tumors, whereas WBS was positive predominantly in low-grade carcinomas, although statistical significance could not be reached. The results prove the clinical usefulness of FDG-PET and MIBI for detection of 131iodine-negative tumor tissue in differentiated thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226199     DOI: 10.1089/thy.1997.7.327

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  16 in total

1.  Intraductal oncocytic papillary neoplasm of the pancreas shows strong positivity on FDG-PET.

Authors:  Takehiro Noji; Satoshi Kondo; Satoshi Hirano; Yoshiyasu Ambo; Eichi Tanaka; Chietsugu Katoh; Eriko Tsukamoto; Nagayoshi Tamaki; Hiroyuki Katoh
Journal:  Int J Gastrointest Cancer       Date:  2002

2.  Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.

Authors:  L S Freudenberg; G Antoch; A Frilling; W Jentzen; S J Rosenbaum; H Kühl; A Bockisch; R Görges
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-12       Impact factor: 9.236

3.  Thymic carcinoid and parathyroid hyperplasia detection with 99mTc-MIBI men type 1.

Authors:  C Marí; J León; J Farrerons; X Matis-Guiu; A Tembl; J C Martin; A Flotats; L l Bernà
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

4.  Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management.

Authors:  Di Wu; Dorina Ylli; Cristiane J Gomes Lima; Wen Lee; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

5.  Combined BRAFV600E analysis and 99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation.

Authors:  A Campennì; R M Ruggeri; M Siracusa; S A Pignata; F Di Mauro; A Vento; F Trimarchi; S Baldari
Journal:  J Endocrinol Invest       Date:  2018-03-16       Impact factor: 4.256

6.  Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.

Authors:  A Frilling; K Tecklenborg; R Görges; F Weber; M Clausen; E C Broelsch
Journal:  Ann Surg       Date:  2001-12       Impact factor: 12.969

7.  Recombinant TSH-stimulated, radioguided differentiated thyroid carcinoma surgery.

Authors:  Michael E Spieth; Steven B Standiford; Marjorie E Starkman; John Gough
Journal:  Clin Med Res       Date:  2003-01

Review 8.  Role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative ¹³¹I scan: review of the literature.

Authors:  Francesco Bertagna; Giorgio Biasiotto; Emanuela Orlando; Giovanni Bosio; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2010-11-27       Impact factor: 2.374

9.  Comparison of diagnostic and prognostic capabilities of ¹⁸F-FDG-PET/CT, ¹³¹I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer.

Authors:  Shigeki Nagamachi; Hideyuki Wakamatsu; Shogo Kiyohara; Ryuichi Nishii; Youichi Mizutani; Seigo Fujita; Shigemi Futami; Hideo Arita; Masaomi Kuroki; Hiroshi Nakada; Noriko Uchino; Shozo Tamura; Keiichi Kawai
Journal:  Jpn J Radiol       Date:  2011-07-24       Impact factor: 2.374

10.  Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.

Authors:  Masahiro Iwata; Kanji Kasagi; Takashi Misaki; Keiichi Matsumoto; Yasuhiro Iida; Takayoshi Ishimori; Yuji Nakamoto; Tatsuya Higashi; Tsuneo Saga; Junji Konishi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.